AT7519M: Clinical Trials

3 trials of AT7519M, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3
Phase 11Completed 1

Follow AT7519M: new trials by email Literature Review of AT7519M trials Research Report on AT7519M

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
AT7519M - Mantle Cell Lymphoma
Phase 2CompletedNCIC Clinical Trials Group122012-09-142023-08-04
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
AT7519M - Chronic Lymphocytic Leukemia
Phase 2CompletedNCIC Clinical Trials Group72012-08-272023-08-04
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
AT7519M, Bortezomib - Multiple Myeloma
Phase 1 / Phase 2CompletedAstex Pharmaceuticals, Inc.182010-11-012024-08-02

Conditions studied

Blood Protein Disorders (1)  ·  Hematologic Diseases (1)  ·  Hemorrhagic Disorders (1)  ·  Hemostatic Disorders (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoproliferative Disorders (1)  ·  Multiple Myeloma (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms, Plasma Cell (1)  ·  Paraproteinemias (1)

Sponsors

NCIC Clinical Trials Group (2)  ·  Astex Pharmaceuticals, Inc. (1)

Countries

Canada (2)  ·  United States (1)

Top investigators

John Kuruvilla (1)  ·  Matthew D Seftel (1)

Results publications

PMID 27750483